Marksans Pharma arm receives EIR from USFDA

Mumbai: Marksans Pharma Limited has announced that its wholly owned subsidiary Time-Cap Laboratories, Inc. has received Establishment Inspection Report (EIR) from US Food & Drugs Administration (USFDA) for the audit conducted in October 2023.

"No 483' s were issued during the Audit," the Company informed ina BSE filing.

Medical Dialogues team had earlier reported that the Company's newly acquired Goa manufacturing facility had successfully undergone inspection from German health authorities.

Read also: Marksans Pharma Goa facility undergoes successful inspection from German Health Authorities

Marksans Pharma Limited headquartered at Mumbai, India is engaged in Research, Manufacturing & Marketing of generic pharmaceutical formulation in the global markets. The company's manufacturing facilities located in India, USA and UK are approved by several leading regulatory agencies including USFDA, UKMHRA and Australian TGA. The company's product portfolio spreads over major therapeutic segments of CVS, CNS, Antidiabetic, Pain Management, Gastroenterological and Antiallergies. The company is marketing these products globally.

Read also: Marksans Pharma bags USFDA nod for Esomeprazole Magnesium Delayed Release Capsules